| Literature DB >> 35310355 |
Dong Liang1, Xiaoyi Zhang1, Yi Wang2, Taotao Huo1, Min Qian1, Yibo Xie1, Wenshuai Li1, Yunqiu Yu1, Wei Shi3, Qianqian Liu3, Junle Zhu4, Chun Luo4, Zhijuan Cao1, Rongqin Huang1.
Abstract
Sensitive detection and accurate diagnosis/prognosis of glioma remain urgent challenges. Herein, dispersed magnetic covalent organic framework nanospheres (MCOF) with uniformed Fe3O4 nano-assembly as cores and high-crystalline COF as shells were prepared by monomer-mediated in-situ interface growth strategy. Based on the unique interaction between MCOF and hairpin DNA, a fluorescent signal amplified miRNA biosensor was constructed. It could realize the sensitive detection of miRNA-182 in different matrixes, where the detection limit, linearity range and determination coefficient (R2) in real blood samples reached 20 fM, 0.1 pM-10 pM and 0.991, respectively. Also, it possessed good stability and precision as observed from the low intra-day/inter-day RSD and high extraction recovery. As a result, it could quantify miRNA-182 in serum of glioma patients, the concentration of which was significantly higher than that of healthy people and obviously decreased after surgery. Finally, a proof-of-concept capillary chip system using this biosensor was proposed to realize the visualized detection of miRNA-182 in microsample. These findings suggest a robust way for sensitive detection and accurate diagnosis/prognosis of glioma.Entities:
Keywords: Blood samples; Fluorescence signal amplification biosensor; Glioma diagnosis; Magnetic COF nanospheres; miRNA detection
Year: 2021 PMID: 35310355 PMCID: PMC8892165 DOI: 10.1016/j.bioactmat.2021.11.033
Source DB: PubMed Journal: Bioact Mater ISSN: 2452-199X
Scheme 1Schematic diagram of synthesis and detection. (A) The dispersed and high-crystalline COF-coated Fe3O4 magnetic nanospheres (MCOF) prepared by monomer-mediated in-situ interface growth strategy. (B) The fluorescent signal amplified miRNA biosensor constructed by using two hairpin DNA probes.
Fig. 1Characterizations of MCOF. (a) TEM images and ED pattern (inset) of magnetic Fe3O4 nano-assembly. (b) TEM image and ED pattern of multiple MCOF nanospheres. (c) TEM image of single MCOF nanosphere. (d) HRTEM image of COF shell. (e) HRTEM image of magnetic Fe3O4 core. (f) STEM image and EDS element mappings of MCOF. (g) XRD pattern of MCOF. (h) FT-IR spectra for monomers (TT, Benzidine), mid products (Fe3O4, Fe3O4@SiO2) and MCOF nanospheres.
Fig. 2Structural analysis of MCOF. (a) XPS survey spectrum and corresponding (b) C 1s, (c) N 1s, (d) O 1s and (e) Fe 2p spectra. (f) Nitrogen adsorption-desorption isotherms and pore size distribution curve.
Fig. 3Optimizations of the fluorescence signal amplification biosensor. (a, b) Fluorescence spectra of the fluorescence signal amplification biosensor for the miRNA biosensing in the absence of H2 and in the simultaneous presence of H1 and H2, respectively. (c–f) Relative fluorescence intensities of the fluorescence signal amplification biosensor for the miRNA biosensing at different hybrid chain reaction temperatures, at different H1 and H2 probe concentrations, with or without magnetic separation, and in different media, respectively.
Fig. 4The miRNA-182 detection using the MCOF-based biosensor and a capillary-assisted visualization system. (a) Relative fluorescence intensities of the MCOF-based biosensor upon exposure to different miRNA molecules. (T: Target miRNA; SM: Single-base mismatch miRNA; FM: Four-base mismatch miRNA; R: Random miRNA. (b) Concentrations of miRNA-182 from blood samples of 12 healthy donors, 12 glioma patients before and after surgery determined by the MCOF-based biosensor. (GP: glioma patients before surgery; AS: after surgery; HD: healthy donors). (c) Concentrations of miRNA-182 from blood samples of 6 glioma patients before and after surgery determined by the MCOF-based biosensor. (GP: glioma patients before surgery; w1: one week after surgery; w2: two weeks after surgery). (d) Fluorescence images and schematic illustration of the capillary-assisted MCOF-based visualized sensing systems upon exposure to different concentrations of miRNA-182 molecules. Data are expressed as Mean ± SD. ***: p < 0.001; ****: p < 0.0001.
Intra-day and inter-day precision, extraction recovery of miRNA-182 assay using the MCOF-based biosensor (mean ± SD, n = 5).
| Concentration (pM) | Inter-day RSD (%) | Intra-day RSD (%) | Extraction Recovery (%) |
|---|---|---|---|
| 5.0 | 3.37 | 1.00 | 92.42 ± 5.04 |
| 2.0 | 4.49 | 2.93 | 96.72 ± 4.01 |
| 1.0 | 6.31 | 3.57 | 98.97 ± 7.15 |
| 0.1 | 6.56 | 2.38 | 94.23 ± 6.46 |
Concentrations of miRNA-182 from blood samples of 12 healthy donors, 12 glioma patients before and after surgery determined by the MCOF-based biosensor.
| Patients before surgery (pM) | Patients after surgery (pM) | Healthy donors (pM) | |
|---|---|---|---|
| 1.656 ± 0.034 | 0.733 ± 0.080 | 0.961 ± 0.074 | |
| 2.415 ± 0.027 | 0.921 ± 0.023 | 0.508 ± 0.085 | |
| 2.105 ± 0.018 | 0.892 ± 0.021 | 1.002 ± 0.029 | |
| 1.575 ± 0.029 | 0.749 ± 0.019 | 0.246 ± 0.038 | |
| 2.767 ± 0.050 | 1.127 ± 0.060 | 0.862 ± 0.069 | |
| 1.704 ± 0.074 | 0.509 ± 0.030 | 0.520 ± 0.084 | |
| 1.961 ± 0.047 | 0.773 ± 0.058 | 0.499 ± 0.063 | |
| 1.582 ± 0.089 | 0.562 ± 0.064 | 0.423 ± 0.094 | |
| 2.242 ± 0.035 | 0.911 ± 0.048 | 0.810 ± 0.082 | |
| 1.933 ± 0.075 | 0.474 ± 0.009 | 0.781 ± 0.088 | |
| 2.409 ± 0.074 | 0.776 ± 0.045 | 0.683 ± 0.084 | |
| 2.014 ± 0.015 | 1.024 ± 0.087 | 1.186 ± 0.054 | |
| 2.036 ± 0.394 | 0.791 ± 0.211 | 0.681 ± 0.274 |